Initiation of Disease‐Modifying Antirheumatic Drugs in Older Medicare Beneficiaries With New Diagnosis of Late‐Onset Rheumatoid Arthritis

Author:

Lee Jiha1ORCID,Martindale Jonathan1,Makris Una E.2,Singh Namrata3,Yung Raymond1,Bynum Julie P. W.1

Affiliation:

1. University of Michigan Ann Arbor

2. University of Texas Southwestern Medical Center and VA North Texas Health Care System Dallas Texas

3. University of Washington Seattle

Abstract

ObjectiveOlder adults with rheumatoid arthritis (RA) account for up to one‐third of the RA population and are less likely to receive optimal treatment. For the subgroup of older adults with late‐onset RA (LORA), who experience more symptomatic and progressive disease, suboptimal treatment could be more consequential than the general population who age with RA. We evaluated use of disease‐modifying antirheumatic drugs (DMARDs) in older adults with a new diagnosis of LORA.MethodsIn this retrospective observational study, we identified adults 66 years of age or older with a new diagnosis of LORA using Medicare data from 2008 to 2017. Information on baseline patient characteristics and DMARD initiation during the first 12 months after LORA diagnosis were collected. We also assessed concomitant use of glucocorticoids (GCs).ResultsWe identified 33,373 older adults with new diagnosis of LORA. Average age at LORA diagnosis was 76.7 (SD 7.6); 75.4% were female, 76.9% were White, and 35.6% had low‐income subsidy (LIS). Less than one‐third were initiated on a DMARD (28.9%). In multivariable analyses, DMARD initiation was associated with younger age, fewer comorbidities, and absence of LIS status. Concomitant long‐term (>3 months) GC use was higher among those on any DMARD (44.3%) compared with those without (15.2%).ConclusionsDMARD initiation after new diagnosis of LORA is low despite current clinical practice guidelines recommending early aggressive initiation of treatment. Long‐term GC use is common among those on any DMARDs, raising concern for suboptimal DMARD use. Further studies are needed to understand drivers of DMARD use in older adults.

Funder

Health Services Research and Development

National Institute of Arthritis and Musculoskeletal and Skin Diseases

National Institute on Aging

Publisher

Wiley

Subject

Rheumatology

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3